Items tagged with Treatment
Responsible use of rifampin for the treatment of latent TB infection (post)
A commentary published in the Canadian Medical Association Journal emphasized the importance of the responsible use of rifampin for the treatment of latent TB. "As rifampin is the most important drug for the treatment of active TB, the development of rifampin resistance carries serious consequences to patients and society."
The fight against TB: researchers at St. Michael’s Hospital identify best practices for the use of antibiotics (post)
Toronto, Canada , July 4, 2019 - Tuberculosis (TB) could develop resistance to rifampin – a crucial antibiotic – if clinicians aren’t vigilant about properly assessing patients for the active form of disease, suggests a paper written by St. Michael’s Hospital scientists and published in the Canadian Medical Association Journal.
Will a new TB treatment be available soon? (post)
MANILA — Experts advising the U.S. Food and Drug Administration on marketed and investigational drugs for infectious diseases and disorders were divided on whether the regulatory agency should approve a new drug as part of a proposed combination therapy for highly resistant tuberculosis.
Rifampin and isoniazid is efficacious in treatment of pleural TB (post)
As a result of low drug resistance in pleural tuberculosis (TB), treatment regimens of pleural TB may include fewer drugs and maintain appropriate levels of efficaciousness, according to a study published in the European Journal of Clinical Microbiology & Infectious Diseases.
India’s reliance on bedaquiline donations limits access to the key anti-TB drug (post)
On 24 March 2016, on the occasion of World Tuberculosis Day, JP Nadda, India’s health minister at the time, announced the launch of bedaquiline in India. Bedaquiline is a new anti-tuberculosis drug that works on patients with drug-resistant TB, or DR-TB. The government announced that it would be giving the drug for free, under a national programme to eliminate TB.
Janssen announces FDA accelerated approval for SIRTURO® as part of combination therapy to treat adolescents with pulmonary MDR-TB (post)
TITUSVILLE, NJ, August 9, 2019 — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted approval for SIRTURO® (bedaquiline) tablets as part of combination therapy in pediatric patients – those over the age of 12 and younger than 18 and weighing at least 66 pounds (30 kilograms) – with pulmonary multidrug-resistant tuberculosis (MDR-TB), when an effective treatment regimen cannot otherwise be provided. Approved under the FDA’s accelerated approval pathway based on time to sputum culture conversion, bedaquiline can now be used as part of combination therapy for eligible MDR-TB patients aged 12 years and over in the U.S. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trials.
Mobile phone intervention reduces TB treatment failure in Kenyan study (post)
In Kenya, patients with tuberculosis who received daily text-based questions about treatment adherence and other mobile phone-based reminders were around two-thirds less likely to fail to complete treatment, according to findings published in The New England Journal of Medicine.
India must test new TB drug: Survivors appeal to Minister Harsh Vardhan (post)
Tuberculosis activists have appealed to Union Health Minister Dr Harsh Vardhan requesting India to test a new TB drug, which has been approved by the USFDA.
Lancet Series: Tuberculosis 2019 (post)
Executive summary
Gout risk during TB treatment higher with obesity, chronic kidney disease, hyperuricemia (post)
Obesity, chronic kidney disease (CKD), and/or pretreatment hyperuricemia increase the risk for gout during tuberculosis (TB) treatment, according to research results published in the International Journal of Rheumatic Diseases.
Page 49 of 105 · Total posts: 0
←First 48 49 50 Last→